INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces two presentations at the upcoming 18th Clinical Trials on Alzheimer’s Disease conference (CTAD), ...

TG Therapeutics, Inc. has seen rapid enrolment of ENHANCE study, which could allow simplified dosing regime of IV Briumvi.

At the conference, Acuitas' Chief Scientific Officer, Dr. Ying Tam, showcased the company's Next-Generation LNP advancements, a comprehensive approach that uses multiple technologies and strategies to ...

Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today reported financial results for ...

Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary endpoints with potential of ...

Ondas Holdings reported third-quarter financial results on Thursday. The transcript from the earnings call has been provided below.

The economics of the software package era were interesting. Each version of a given software package was to be written, ...

In a financial presentation following rumors, Square Enix stated it would 'close overseas development studios' and shift ...

Furukawa told investors that the updated hardware is the “new standard for the Nintendo Switch concept” and that it will now shift its “primary development focus to Nintendo Switch 2 and expand our ...

As of September 30, 2025, Corvus had cash, cash equivalents and marketable securities of $65.7 million as compared to $52.0 million as of December 31, 2024. Consistent with last quarter, Corvus ...

A proposal for a new business park near the Silverstone race circuit has been rejected by councillors An industrial site proposed by a developer has been rejected by a council, following 570 ...

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and ...